{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:17Z","timestamp":1758937217971,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.leukres.2022.106837","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T01:20:56Z","timestamp":1648344056000},"page":"106837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission"],"prefix":"10.1016","volume":"116","author":[{"given":"Phillip C.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Donati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Vassili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ing S.","family":"Tiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.106837_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.leukres.2022.106837_bib2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106837_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and disposition of a novel B-Cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.leukres.2022.106837_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-016-0485-9","article-title":"Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers","volume":"37","author":"Salem","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.leukres.2022.106837_bib5","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dkq121","article-title":"Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort","volume":"65","author":"Vehreschild","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.leukres.2022.106837_bib6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.leukres.2022.106837_bib7","unstructured":"Abbvie. 2021 11 December 2021. Dosing and drug interactions. \u3008https:\/\/www.venclextahcp.com\/aml\/dosing\/drug-interactions.html\u3009. 11 December 2021."},{"key":"10.1016\/j.leukres.2022.106837_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106837_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2018.03.006","article-title":"Time to repeal and replace response criteria for acute myeloid leukemia?","author":"Bloomfield","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2022.106837_bib10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/ii study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106837_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106837_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","author":"Rausch","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2022.106837_bib13","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2022.106837_bib14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid Leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.leukres.2022.106837_bib15","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2022.106837_bib16","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/bloodadvances.2019000306","article-title":"Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML","volume":"3","author":"Murphy","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2022.106837_bib17","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2022.106837_bib18","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:19Z","timestamp":1758934939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":18,"alternative-id":["S0145212622000637"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106837","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106837"}}